

34th Annual Meeting of the European Association for the Study of Diabetes

Barcelona, Spain, September 1998

Abstracts

Index of Oral Presentations

OP 1	Indices of Glucose-Intolerance	A 3
OP 2	Therapeutic Aspects of Diabetic Nephropathy	A 4
OP 3	Experimental and Clinical Islet Transplantation	A 6
OP 4	Diabetes and Pregnancy-Clinical Aspects	A 7
OP 5	T-Cells in Type 1 Diabetes	A 9
OP 6	Defect Insulin Signalling Yields Insulin Resistance	A 10
OP 7	Antigens and Antibodies in Type 1 Diabetes	A 12
OP 8	Ion Channel Activity in β -Cells	A 13
OP 9	Exercise	A 15
OP 10	Lipids and Late Complications	A 16
OP 11	Retinopathy	A 18
OP 12	GLP	A 19
OP 13	Epidemiology of Type 1 Diabetes	A 21
OP 14	Islet Metabolism and Insulin Release	A 22
OP 15	Cellular Mechanisms of Vascular Dysfunction	A 24
OP 16	Lipids and Insulin Resistance	A 25
OP 17	Glycation	A 27
OP 18	Immunology and Diabetic Pregnancy	A 28
OP 19	Cardiovascular Disease, Risk Factors, Prediction and Genetics	A 30
OP 20	Genetics of Type 2 Diabetes	A 32
OP 21	Oxygen Radicals Cause Insulin Resistance	A 34
OP 22	Regulation of Insulin Exocytosis	A 36
OP 23	Pathophysiology of Diabetic Nephropathy	A 38
OP 24	Education, Outcome, Health Care Costs	A 40
OP 25	Myocardial Infarction in Diabetes	A 42
OP 26	Early Type 2 Diabetes	A 43
OP 27	Altered Intra Uterine Development and Insulin	A 44
OP 28	Devices	A 45
OP 29	Nutrition and Diet Therapy	A 46
OP 30	Transcriptional Control in β -Cells	A 47
OP 31	New Forms of Insulin Therapy	A 48
OP 32	Neuropathy	A 50
OP 33	Insulin Signal Transduction	A 52
OP 34	Nitric Oxide Vascular Reactivity	A 54
OP 35	Susceptibility and Resistance to β -Cell Damage	A 56
OP 36	Diabetic Embryopathy-Clinical and Experimental Advances	A 58
OP 37	New Therapies for Type 2 Diabetes	A 60
OP 38	Animal Models of Type 1 Diabetes	A 62
OP 39	Leptin in Obesity and Pregnancy	A 64
OP 40	Development and Regeneration of β -Cells	A 66
OP 41	Hypoglycaemia	A 68
OP 42	Epidemiology of Type 2 Diabetes	A 70
OP 43	Genetics of Type 1 Diabetes	A 72
OP 44	Risk Factors of the Diabetic Foot	A 73
OP 45	Quality of Life	A 74
OP 46	PKC-Activation and Vascular Function	A 75
OP 47	Patterns of Insulin Secretion from β -Cells	A 76
OP 48	Alterations in Glucose Metabolism	A 77

Index of Poster Presentations

PS 1	Genetics of Type 1 Diabetes	A 78
PS 2	Epidemiology of Type 1 Diabetes	A 82
PS 3	Prediction and Prevention of Type 1 Diabetes	A 86
PS 4	Environmental Factors	A 91
PS 5	Clinical Immunology	A 92
PS 6	Experimental Immunology	A 100
PS 7	Genetics of Type 2 Diabetes	A 104
PS 8	Epidemiology of Type 2 Diabetes	A 115
PS 9	Prediction and Prevention of Type 2 Diabetes	A 125
PS 10	β -Cell Development, Replication and Insulin Gene Expression	A 128

PS 11	Signal Transduction in β -Cells	A 133
PS 12	Ion Channels and Exocytosis	A 138
PS 13	Modulation of Insulin Secretion	A 150
PS 14	Cytokines and β -Cell Degeneration	A 154
PS 15	Islet and Pancreas Transplantation	A 163
PS 16	Amylin	A 166
PS 17	LADA	A 170
PS 18	Insulin Action: Signal Transduction and Insulin Resistance	A 171
PS 19	Insulin Action: Cardiovascular Effects	A 174
PS 20	Hormonal Action (Other)	A 176
PS 21	Hormone Receptors	A 179
PS 22	Glucose Transport	A 181
PS 23	Gastro-Entero-Pancreatic Factors	A 182
PS 24	Insulin Resistance: Tissue and Cellular Level	A 185
PS 25	Insulin Resistance: Intracellular	A 188
PS 26	Insulin Resistance: Cardiovascular	A 191
PS 27	Insulin Resistance: Whole Body	A 194
PS 28	Insulin Sensitivity: Methods	A 199
PS 29	Carbohydrate Metabolism	A 200
PS 30	Carbohydrate Metabolism: Hepatic Glucose Production	A 202
PS 31	Protein Metabolism	A 204
PS 32	Lipids I	A 205
PS 33	Lipoproteins	A 207
PS 34	Free Fatty Acids	A 209
PS 35	Obesity	A 212
PS 36	Treatment of Obesity	A 214
PS 37	Animal Models of Obesity	A 215
PS 38	Obesity and TNF α	A 217
PS 39	Leptin	A 218
PS 40	Clinical Diabetes	A 222
PS 41	Devices	A 226
PS 42	Pharmacological Agents	A 230
PS 43	Hypoglycaemia	A 240
PS 44	Insulin Therapy I	A 242
PS 45	Insulin Therapy II	A 247
PS 46	Diabetes Education – Health Care Delivery	A 250
PS 47	Psychology	A 255
PS 48	Clinical Pregnancy	A 256
PS 49	Experimental Pregnancy	A 261
PS 50	Exercise	A 263
PS 51	Nutrition and Diet Therapy	A 265
PS 52	Gastrointestinal Autonomic Neuropathy	A 267
PS 53	Neuropathy	A 270
PS 54	Diabetic Foot	A 275
PS 55	Retinopathy	A 280
PS 56	Treatment of Diabetic Nephropathy	A 284
PS 57	Clinical Nephropathy	A 285
PS 58	Genetics of Diabetic Nephropathy	A 293
PS 59	Pathogenesis of Diabetic Nephropathy	A 297
PS 60	Glycation	A 301
PS 61	Autonomic Neuropathy	A 303
PS 62	Endothelium and Vasomotion	A 309
PS 63	Endothelium in Vitro Studies	A 316
PS 64	Markers of Endothelial Damage	A 318
PS 65	Adhesion Molecules and Vascular Complications	A 320
PS 66	Oxidative Stress and Complications	A 321
PS 67	Bone Density	A 325
PS 68	Pathogenic Mechanisms of Complications	A 326
PS 69	Platelets, Coagulation, Rheology	A 328
PS 70	Atherosclerosis	A 333
PS 71	Homocysteine and Cardiovascular Disease	A 336
PS 72	Hypertension	A 338
PS 73	Coronary Heart Disease	A 342
PS 74	Lipids II	A 346
PS 75	Cardiovascular Risk Factors and Mortality	A 350

548

GLIBENCLAMIDE IMPAIRMENT OF β CELL FUNCTION INVOLVES ALTERATIONS OF CYTOPLASMIC Ca^{2+} REGULATION.

M. Anello, P. Gilon and J.C. Henquin. Unité d'Endocrinologie et Métabolisme, University of Louvain, Brussels, Belgium.

Chronic treatment with glibenclamide alters the β cell response to various insulin secretagogues. The possible mechanisms have been studied with islets cultured for 18h in the presence of 10 mmol/l glucose, with (test) or without (control) a therapeutic concentration of glibenclamide (10 nmol/l). Acute responses of the islets were then determined in the absence of glibenclamide. Insulin release from test islets was unaffected by sulphonylureas or diazoxide because the drugs failed to increase and decrease $[\text{Ca}^{2+}]_i$ that was already elevated in the absence of any stimulus. The responsiveness to glucose was preserved but modified in several respects. As compared with controls, insulin release by test islets was increased in the absence of glucose, and mainly stimulated between 0-10 instead of 7-20 mmol/l glucose. The maximum response was halved, but this difference disappeared after correction for the decrease in insulin content. The first phase of glucose-induced insulin secretion was abrogated because of a paradoxical decrease of the high basal $[\text{Ca}^{2+}]_i$ in β cells. The second phase was preserved but occurred with little rise of $[\text{Ca}^{2+}]_i$. These abnormalities did not result from alterations of glucose metabolism (NADPH fluorescence). In islets cultured with tolbutamide, glucose-induced $[\text{Ca}^{2+}]_i$ and insulin changes were normal, except for a lower maximal secretion rate due to the fall in insulin content. These islets, however, behaved like those cultured with glibenclamide if tolbutamide remained present during the acute functional tests. In conclusion, treatment with a low glibenclamide concentration perturbs β cell function by permanently blocking K^+ -ATP channels and raising $[\text{Ca}^{2+}]_i$. Glucose stimulation of insulin secretion occurs at lower concentrations, is delayed and is largely mediated by a modulation of Ca^{2+} action on exocytosis.

550

ENGINEERED PEPTIDES FROM THE H3 DOMAIN OF SYNTAXIN INHIBIT INSULIN RELEASE IN INTACT MOUSE PANCREATIC β CELLS.

F. Martin*, E. Salinas*, J. Vazquez*, B. Soria* and J. A. Reig*. Departments of *Sciences and Technology, *Neurochemistry, Physiology* and Institute of Bioengineering, University of Miguel Hernandez, Campus de San Juan, 03550 Alicante; *Center of Molecular Biology, School of Sciences, University Autonoma of Madrid, Cantoblanco, 28049 Madrid, Spain.

Recent studies show that syntaxin-1 is implicated in the calcium-dependent secretory pathway in pancreatic endocrine β -cells. Moreover, the functional role of two 23rd segments (Syn A and SynB) of the H3 domain of syntaxin-1 have been demonstrated. In the present study, we have established in intact β -cells a minimal functional active zone of 17 residues of the H3 domain of syntaxin-1, as the very effective uncoupling element of Syn A segment. 13th peptides (Syn-1 to Syn-6) from peptides Syn A, Syn I and one additional peptide, with the same amino acid composition than Syn I but in random sequence to be used as controls (Syn I_c) were synthesized by t-boc chemistries using an automated solid-phase peptide synthesizer. Peptides were purified by RP-HPLC. The second portion of 13th peptides Syn I and Syn I_c were subjected to myristoylation. After deprotection of the amino terminus of the peptides, myristic acid was activated "in situ" with BOP. Functional experiments were carried out in digitonin-permeabilized and intact cells incubated for 10 and 30 min respectively, in the presence of the different synthetic peptides. Insulin was determined by RIA. Basal or stimulated secretion were measured in media containing 5 mmol/l EGTA, 10 $\mu\text{mol/l}$ Ca^{2+} or 22 mmol/l glucose. 200 $\mu\text{mol/l}$ of peptides Syn-2, Syn-3 and Syn-4 inhibited Ca^{2+} -dependent insulin release ($p < 0.0001$, $n = 6$) in permeabilized cells. No additive effects were observed when Syn-2 to Syn-4 were incubated together ($n = 4$). myr-Syn I provoked a dose-dependent inhibition of 22 mmol/l glucose-induced insulin release ($\text{IC}_{50} \sim 23 \text{ mmol/l}$) in intact cells ($n = 4$). myr-Syn I_c had not inhibitory effect at 300 $\mu\text{mol/l}$ ($n = 4$). These data demonstrated for the first time, that nutrient-induced secretory process can be uncoupled in intact β -cells by using specific peptides and support previous studies concerning the direct role of specific regions of syntaxin-1 in the insulin exocytotic process.

549

AMINO ACID TRANSFORMATION OF OSCILLATORY Ca^{2+} SIGNALS IN MOUSE PANCREATIC B-CELLS AND INTACT ISLETS

M. Ahmed¹, L. Ali¹, E. Grapengiesser² and B. Hellman². ¹BIRDEM, Dhaka, Bangladesh and ²Department of Medical Cell Biology, University of Uppsala, Uppsala, Sweden

Glucose-induced increase of cytoplasmic Ca^{2+} in pancreatic B-cells is usually manifested as slow oscillations from the basal level. The significance of this rhythmicity for maintaining normal B-cell function with periodic variations of circulating insulin made it of interest to investigate how the oscillatory Ca^{2+} signal was affected by various amino acids. Cytoplasmic Ca^{2+} was measured in individual B-cells and islets from ob/ob mice using dual wavelength microfluorometry and the indicator fura-2. The individual B-cells were very sensitive to alanine, glycine and arginine. When added at concentrations as low as 0.1 mM and 0.5 mM, each of these amino acids transformed the oscillations into sustained elevation of cytoplasmic Ca^{2+} in 30 and 60 % respectively of the B-cells. Stimulation of the entry of Ca^{2+} , obtained either by raising the extracellular concentration or by prolonging the open state of the voltage-dependent Ca^{2+} channels with BAY K 8644, resulted in reappearance of the rhythmic activity. Oscillatory Ca^{2+} signals in intact islets were more resistant to transformation by amino acids than those of individual B-cells. Even at 10 mM of glycine, alanine or arginine sustained elevation was observed in only about 55% of the islets. It is suggested that signals from the adjacent cells make it possible for B-cells situated in islets to overcome a suppression of the oscillatory activity otherwise seen in the presence of amino acids.

551

COUPLING OF THE α -LATROTOXIN RECEPTOR LATROPHILIN TO INSULIN EXOCYTOSIS IN CLONAL β -CELLS

J. Lang¹, C. B. Wollheim¹, M. Pescatori², R. A. Fisher³, A. Grasso⁴ and Y. Ushkaryov⁵

¹Div. de Biochimie Clinique, Dép. de Médecine Interne, CMU, Genève, Switzerland; ² Università di Roma, Roma, Italy, ³ Dep. of Pharmacology, University of Iowa, Iowa City, USA, ⁴ Istituto di Biologia Cellulare, CNR, Roma, Italy; and ⁵ Dep. of Biochemistry, Imperial College, London, UK

The black-widow spider venom component α -latrotoxin (α -LTX) induces massive exocytosis in neurons and evokes exocytotic insulin release in primary β -cells as well as in the clonal cell lines MIN6 and INS-1, but not in HIT-T15 or RINm5F cells. The effect of α -LTX in insulin secreting cells is mediated by latrophilin (LPH), a class II G-protein coupled receptor.

We have investigated the coupling of latrophilin to exocytosis in HIT-T15 cells. Transient transfection of full-length cDNA coding for LPH induced dose dependent insulin release with an EC_{50} of 0.5 nM for its agonist α -LTX. LPH was targeted to discrete areas of the plasma membrane as evidenced by confocal immunocytochemistry. The agonist dependent insulin release is of vesicular origin as it was blocked by co-expression of the light chains of the botulinum neurotoxins C1 or E known to cleave syntaxin and SNAP-25, respectively. Coupling of LPH to insulin release was specifically reproduced in streptolysin-O permeabilized cells by a receptor-mimetic peptide corresponding to an intracellular loop of LPH. Therefore it involves most likely heterotrimeric G-proteins. However, the effect of α -LTX was insensitive to pertussis toxin. Moreover, the effect of α -LTX on insulin release was not altered by concomitant overexpression of the Regulators of G-protein Signalling RGS3 and RGS3-t, which impeded stimulation of hormone secretion by carbachol and PACAP.

We conclude that latrophilin is capable of mediating the effects of α -LTX on insulin exocytosis and induces vesicular release of insulin by coupling to a heterotrimeric G-protein distinct from $G_{i/o}$, G_{α_s} or G_{α_q} .